REG - Cizzle Biotechnology - Update on Licensing and Partnership Agreement

Cizzle Biotechnology HoldingsAnnouncement

03/10/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241003:nRSC8688Ga&default-theme=true

RNS Number : 8688G  Cizzle Biotechnology Holdings PLC  04 October 2024

3 October 2024

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Further Update on Strategic Licensing and Partnership Agreement for North
America

Cizzle Biotechnology, the UK based diagnostics developer, today provides a
further update on progress with the Company's planned strategic and exclusive
licensing partner in the USA, Cizzle Bio Inc ("BIO").

Following the Company's signing of a memorandum of understanding ("MoU") with
BIO announced on 2 April 2024 and the 60 day extension to finalise a full and
binding license agreement (the "Agreement") announced on 25 July 2024, the
Company has continued to support BIO's plans to market the Company's CIZ1B
biomarker and to complete the Agreement. The final details of the Agreement
are expected to be completed shortly, at which time the Company will make a
further announcement.

In the meantime, BIO continues to attract significant clinical interest to
build on the recent collaboration with Moffitt Cancer Center, the number one
cancer hospital in Florida and the Southeast USA, to test patients with
suspicious lung nodules, as announced on 9 September 2024.

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                     +44(0) 20 3328 5656
 John Depasquale/George Payne (Corporate Finance)
 Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Cizzle is developing a blood test to help in the early detection of lung
cancer. Based on the pioneering work of Professor Coverley and colleagues, at
the University of York, on a naturally occurring cell nuclear protein
involved in DNA replication called CIZ1, they discovered that a variant
called CIZ1B is highly associated with the presence of early-stage cancer. The
company has now entered into commercial royalty bearing licensing agreements
and collaborations with leading centres of excellence in cancer for the use of
its proprietary technology as part of its strategy to bring its non-intrusive,
cost-effective blood test to market. Cizzle was admitted to the Standard
segment of the main market of the London Stock Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

About Cizzle Bio Inc

Cizzle Bio Inc, a company registered in Texas USA,  stands at the forefront
of biotechnological innovation, dedicated to revolutionizing the detection of
lung cancer through groundbreaking diagnostic tools. With exclusive rights to
detect the CIZ1B Biomarker in the USA and Canada, we are driven by a
commitment to improve early cancer detection and enhance patient outcomes.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFXLFBZBLZFBE